The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Outpatient administration of CAR T-cell therapies in patients with hematological malignancies
|
A single-center retrospective analysis reported outcomes of outpatient administration of commercially available chimeric antigen receptor (CAR) T-cell therapies, using a strategy of no remote monitoring and early intervention for cytokine release syndrome (CRS).1 This analysis included 58 adult patients with hematological malignancies (multiple myeloma, 33; lymphoma, 24; acute lymphoblastic leukemia, 1) who received a commercial CAR T-cell therapy from January 2022 onwards. Results were published in Blood Advances by Furqan et al.1 |
| Key learnings |
|
In total, 72% of patients were admitted to the hospital in the first 30 days; 40% in Days 0–3, 38% in Days 4–7, and 22% in Days 8–30, with the most common reason for hospitalization being CAR T-cell-related toxicities. |
|
Early outpatient intervention using tocilizumab for Grade ≥1 CRS effectively reduced hospitalization rates, as demonstrated by the 15 out of 35 patients who received tocilizumab for CRSavoiding admission. |
|
The analysis reported a low rate of non-relapse mortality (1.7% at 1 month and 3.4% at 6 months in patients with lymphoma; 0% at 1 and 6 months in patients with multiple myeloma), suggesting that this strategy does not compromise patient safety. |
|
The results suggest that implementing CAR T-cell administration in an outpatient setting is safe and feasible without intensive remote monitoring using an early CRS intervention strategy and may lead to reduced healthcare resource utilization and improved patient quality of life by minimizing hospital admissions.
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with T-cell acute lymphoblastic leukemia do you see in a year?
